Share

Access to Health Care

ACS CAN advocates for policies that provide access to treatments and services people with cancer need for their care - including those who may be newly diagnosed, in active treatment and cancer survivors.

Prescription Drug Affordability Resources:

A majority of cancer patients and survivors struggle to afford cancer care and over 80% have had to make financial sacrifices to cover their health care expenses. This survey also reveals ways that affordability concerns can negatively impact care and treatment, and explores issues related to prescription drug coverage and pain management options.

Many cancer patients take multiple drugs as part of their treatment – often for many months or years. While drugs are not the only costly part of cancer treatment, finding ways to reduce these costs for patients and payers will significantly reduce the overall cost burden of cancer.

This Survivor Views survey examined access to and affordability of cancer care. Survivors report insurance-related barriers to obtaining prescriptions, and lower-income respondents in particular have difficulty affording them.  24% of respondents have received a surprise medical bill, 60% of which were more than $500.

Biological drugs, commonly referred to as biologics, are a class of drugs that are produced using a living system, such as a microorganism, plant cell, or animal cell. Like all drugs, biologics are regulated by the United States Food and Drug Administration (FDA).

For an individual with specific health care needs – like cancer patients and survivors – the drugs covered by a health plan and corresponding cost sharing for each drug is important information when choosing health insurance. However, to make an informed choice, formulary information must be disclosed to the individual.

  •  

Private Health Insurance Resources:

ACS CAN submitted comments regarding a proposed rule to change Health Reimbursement Arrangements (HRAs) and other account-based group health plans.

  •  

Medicare Resources:

The American Cancer Society Cancer Action Network (ACS CAN) submitted comments to the Senate Finance Committee on the Request for Information: Commonsense Policy Options to Lower Drug Prices for Patients.

The American Cancer Society Cancer Action Network (ACS CAN) submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule.

Growing drug costs in the United States are placing pressure on health plans to implement strategies to balance drug expenditures and utilization. Utilization management (UM) tactics are frequently used across public and private insurance plan types to control prescription drug spending.

As drug costs in the United States rise, health insurance plans are implementing strategies to balance expenditures and utilization. Plans can employ utilization management (UM) tactics to mitigate prescription drug spending.

The American Cancer Society Cancer Action Network (ACS CAN) submitted comments to the Department of Health and Human Services (HHS) on the Interoperability Standards and Prior Authorization for Drugs Proposed Rule.

ACS CAN also developed a one pager on prior authorization and its impact on cancer patients. 

The American Cancer Society Cancer Action Network (ACS CAN) submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the Medicare Drug Price Negotiation Initial Price Applicability Year (IPAY) 2028 public engagement process, including results from patient-experience surveys

The American Cancer Society and the American Cancer Society Cancer Action Network provided joint comments to CMS on the the proposed decision memo for changes to the existing National Coverage Decision (NCD) 210.3 related to screening for colorectal cancer (CRC) using non-invasive biomarker tests

ACS CAN filed a comment letter regarding the policies included in the Global Benchmark for Efficient Drug Pricing (GLOBE) Model proposed rule.

ACS CAN filed a comment letter regarding the policies included in the Guarding U.S. Against Rising Drug Costs (GUARD) Model proposed rule.

Medicaid Resources:

Learn how the new HHS interim final rule implementing Medicaid work requirements will impact people with cancer and their caregivers.

ACS CAN submitted comments on CMS' interim final rule implementing community engagement requirements in Medicaid. We expressed serious concerns about how the agency is implementing the medically frail exemption and verification processes, and urged them to change these policies in the final rule. 

Our latest Survivor Views survey finds that 90% of cancer patients and survivors had to miss hours of work, school or volunteering due to their cancer care and treatment. While 80% say this occurred during active treatment, 32% continued to experience disruptions into survivorship. The time missed was significant; 42% of these individuals had to miss 13 or more weeks and 68% report the time missed was inconsistent throughout their experience.

Medicaid is a critical source of health insurance and coverage for more than 77 million Americans, including people with cancer who rely on the program for prevention, timely detection, treatment, and survival. The 2025 budget reconciliation bill makes significant changes to key Medicaid funding mechanisms like state-directed payments and provider taxes, which are expected to reduce states’ ability to finance their Medicaid programs. This factsheet outlines what these changes mean, the projected financial impact on states, and consequences for patient access to cancer care.

ACS CAN submitted comments to CMS opposing Montana's 1115 waiver application to implement work requirements and premiums in their Medicaid program.

ACS CAN opposes policies that condition Medicaid enrollment on work or reporting of work. 

ACS CAN opposes Utah’s proposal to implement work requirements in its Medicaid program, and we urge CMS to reject the amendment request.

ACS CAN supports this demonstration application and urges the Centers for Medicare and Medicaid Services to approve it.